HTG Molecular Diagnostics reported its Q1 2022 financial results, revealing a revenue of $1.2 million, down from $1.4 million in Q1 2021. The net loss from operations increased to $6.3 million compared to $4.6 million the previous year, with a net loss per share of $(0.81). Despite these challenges, the company secured approximately $7.2 million from a private placement. Business highlights include the launch of a proof-of-approach white paper and enhancements to the HTG EdgeSeq technology, aiming to streamline processes for clients.
HTG Molecular Diagnostics (Nasdaq: HTGM) will release its financial results for Q1 2022 on May 12, 2022, after market close. A conference call is scheduled for 4:30 PM ET to discuss the results and provide a corporate update. HTG focuses on advancing precision medicine through transcriptome-wide profiling, aiding translational research, clinical diagnostics, and targeted therapeutics. Its proprietary RNA platform aims to revolutionize drug discovery and diagnostics across various disease areas.
HTG Molecular Diagnostics has appointed Christina M. Carruthers, Ph.D. as Vice President of Target Strategy and Early Development, enhancing its therapeutics team. Dr. Carruthers brings extensive drug discovery and development experience from leading roles at Moderna, Janssen, and other companies. Her expertise is expected to benefit HTG’s proprietary RNA platform, which aims to innovate drug discovery. This strategic hire aligns with HTG's commitment to advancing precision medicine and the development of small molecule therapeutic candidates.
HTG Molecular Diagnostics has announced a significant upgrade to its sample preparation process for the miRNA Whole Transcriptome Assay (miRNA WTA), allowing harmonization with the HTG Transcriptome Panel (HTP). This innovation enables the analysis of nearly 20,000 gene mRNA and over 2,000 miRNA from a single sample lysate, improving workflow efficiency. The new protocol is validated for various sample types including FFPE tissue. The company believes this advancement will enhance multiomic expression analysis and provide a competitive edge in tissue-preserving gene expression profiling.
HTG Molecular Diagnostics has released a proof-of-approach white paper highlighting their innovative drug discovery methodology utilizing the HTG Transcriptome Panel (HTP). This approach aims to accelerate the drug discovery process, improving treatment delivery to patients. The HTP allows assessment of approximately 20,000 mRNA targets and differs from other tools by offering high reproducibility and minimal sample requirements. HTG plans to publish further white papers and continue enhancing its platform for future therapeutic targets.
HTG Molecular Diagnostics (Nasdaq: HTGM) reported its financial results for 2021, showing total revenue of $8.9 million, a modest increase from $8.5 million in 2020. Product-related services revenue rose 13% to $8.9 million. The company's HTG Transcriptome Panel became its top-selling assay within five months of launch, contributing approximately 16% to total revenue. Despite a net loss of $17.1 million, improved from $20.9 million in 2020, cash reserves stood at $21.9 million. Recent expansions include a strengthened therapeutics team and a $7.5 million private placement.
HTG Molecular Diagnostics (Nasdaq: HTGM) announces it will report its financial results for the fiscal year ended December 31, 2021, on March 29, 2022, after market close. A conference call with investors is scheduled for the same day at 4:30 PM ET to discuss the results and provide corporate updates. HTG focuses on advancing precision medicine through its innovative transcriptome profiling technology, enhancing the development of life science tools and clinical diagnostics.
HTG Molecular Diagnostics (Nasdaq: HTGM) has announced a definitive securities purchase agreement for a private placement, expected to raise approximately $7.5 million. HTG will issue 3,244,987 units at $2.312 per unit, with each unit including common stock and warrants. The private placement is set to close on or about March 21, 2022, subject to customary closing conditions. Proceeds will be utilized for working capital and corporate purposes. The securities are unregistered under the Securities Act of 1933 and will require a resale registration statement with the SEC.
HTG Molecular Diagnostics appoints Dr. Robert Spitale to its Scientific Advisory Board, enhancing its expertise in RNA research. Dr. Spitale, an internationally recognized chemical biologist from UC Irvine, specializes in RNA structure and gene expression. His insights are expected to aid HTG's efforts in defining therapeutic targets for various medical needs. Dr. Spitale's extensive background includes numerous prestigious awards, reflecting his significant contributions to genomics and cell biology. This appointment aims to accelerate HTG's precision medicine initiatives through innovative drug development.
HTG Molecular Diagnostics (Nasdaq: HTGM) has appointed Christopher Kiritsy to its Board of Directors. Kiritsy, a seasoned biopharmaceutical industry expert, co-founded Arisaph Pharmaceuticals and served as its CEO, enhancing its drug discovery capabilities. His extensive experience includes a key role in building Kos Pharmaceuticals, contributing to its initial public offering and raising $500 million in public equity. HTG expects Kiritsy's expertise in corporate development and finance to bolster its therapeutic business as it aims to innovate in drug development.